PACKAGE: All 3 Webinars in 2025 Prevent Cancer Dialogue Series
-
Register
- General Attendee - Free!
- Speaker - Free!
- Prevent Cancer Foundation Staff - Free!
The 2025 Prevent Cancer Dialogue series consists of three webinars:
- April 2 - Updates on young-onset cancers: What to know and public health implications
- June 4 - Diversifying clinical trial participation: Pathways from screenings to trials
- October 8 - Minimal Residual Disease (MRD): Exploring the impact on cancer early detection and personalized care
-
Contains 7 Component(s), Includes Credits Includes a Live Web Event on 04/02/2025 at 1:00 PM (EDT)
In this session, speakers will provide an update on the latest information related to young-onset breast and colorectal cancers, as well as current research, known risk factors and potential strategies to address this alarming trend.
Cases of young-onset cancer – cancer diagnosed in individuals ages 18-49 – have been rising at alarming rates. What do we really know about this trend? What do providers need to understand so that symptoms aren’t missed in their younger patients? In this session, speakers will provide an update on the latest information related to young-onset breast and colorectal cancers, as well as current research and known risk factors. We will also explore potential strategies to address this concerning trend. Moderated discussion and Q&A will immediately follow speaker presentations.
Learning objectives for this session:
- Identify current incidence rates and trends related to young-onset breast and colorectal cancers.
- Describe current research on the increase in young-onset breast and colorectal cancers.
- Discuss possible risk factors for young-onset breast and colorectal cancers.
- Identify strategies to inform healthcare providers and the public of young-onset cancer trends and action steps for better health outcomes.
Kimmie Ng, MD, MPH
Dana-Farber Cancer Institute and Harvard Medical School
Dr. Kimmie Ng is Associate Chief of the Division of Gastrointestinal Oncology at Dana-Farber Cancer Institute (DFCI), and Associate Professor of Medicine at Harvard Medical School. She also serves as the Founding Director of the Young-Onset Colorectal Cancer Center and Co-Director of the Colon and Rectal Cancer Center at DFCI. Her research focuses on identifying dietary, plasma, and molecular predictors of improved survival in patients with colorectal cancer, with a special interest in the vitamin D pathway, microbiome, and young-onset colorectal cancer. She is the recipient of numerous NIH, foundation, and industry grants to support this work. She chaired the American Society of Clinical Oncology (ASCO) Scientific Program Committee for the 2023 Annual Meeting and currently serves as a member of ASCO’s Nominating Committee. She was appointed an Associate Editor of JAMA (Journal of the American Medical Association) in February 2024. She has been featured in multiple national media outlets, including the TODAY Show, ABC News, The New York Times, CNN, and The Washington Post, to raise awareness of young-onset colorectal cancer and the importance of cancer screening. Dr. Ng obtained her Bachelor of Science degree with Distinction from Yale University and her Doctor of Medicine degree from University of Pennsylvania Perelman School of Medicine. She completed a residency in internal medicine at University of California, San Francisco (UCSF) and a medical oncology fellowship at Dana-Farber/Partners Cancer Care. She subsequently received a Master of Public Health degree from Harvard T.H. Chan School of Public Health.
Nelli Zafman, CRNP, MSN, OCNP
The Sidney Kimmel Comprehensive Cancer Center
Nelli Zafman is a nurse practitioner and holds a Master of Science in Nursing degree from Johns Hopkins University School of Nursing. She has been working at Sydney Kimmel Cancer Canter, Johns Hopkins University School of Medicine, for the last 18 years. Part of her career there she has been taking care of women and men with a history of early and metastatic breast cancer. Ms. Zafman is ANCC certified and holds an Advanced Oncology Certified Nurse Practitioner, ONS certification. She has also been participating in therapeutic studies looking at management of early-stage as well as late-stage breast cancer.
Michael Williams
The Williams Group
The Williams Group is led by Michael “Mike” Williams. Mr. Williams has more than two decades of experience in business advocacy and strategic communication, as well as federal and state government service. Prior to founding The Williams Group, he was a managing director of Credit Suisse in the Public Policy Americas division. Mr. Williams served as special assistant to the president and staff Director for legislative affairs during the Clinton administration. He has worked in numerous election campaigns at all levels and has served as a congressional liaison for the National Democratic Convention for over 14 years.
Certified Health Education Specialist (CHES):
Sponsored by the Prevent Cancer Foundation (provider number 125052), a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc., this program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 1.5 total Category I Continuing Education Contact Hours (CECH). Maximum advanced-level Continuing Education Contact Hours available are 0. Continuing Competency credits available are 1.5. Content will be provided in the following areas of responsibility for health education specialists: Area V: Advocacy.
Nursing:
This activity has been evaluated and approved by the Continuing Education Approval Program of the National Association of Nurse Practitioners in Women's Health for 1.5 CE continuing education contact hours. NPWH Activity number 25-09-01. CA CEP Number 13411.
-
Contains 5 Component(s) Includes a Live Web Event on 06/04/2025 at 1:00 PM (EDT)
In this session, speakers will share best practices and key barriers in connecting patients to clinical trials following a cancer diagnosis. We will explore novel approaches to improve patient recruitment, retention and equitable access to clinical trials.
In this session, speakers will share best practices and key barriers in connecting patients to clinical trials following a cancer diagnosis. We will explore novel approaches to improve patient recruitment, retention and equitable access to clinical trials. More details to come!
This program is planning to offer continuing education credits for Certified Health Education Specialists (CHES), nurses, and advanced practice nurses. Please check back for more details soon!
-
Contains 5 Component(s) Includes a Live Web Event on 10/08/2025 at 1:00 PM (EDT)
In this session, speakers will delve into the cutting-edge science of Molecular Residual Disease (MRD) testing, a revolutionary approach to cancer detection. We’ll explore how these tests can help determine prognosis/relapse risk, find early recurrence and individualize treatment to improve patient outcomes.
In this session, speakers will delve into the cutting-edge science of Molecular Residual Disease (MRD) testing, a revolutionary approach to cancer detection. We’ll explore how these tests can help determine prognosis/relapse risk, find early recurrence and individualize treatment to improve patient outcomes. More details coming soon!
This program is planning to offer continuing education credits for Certified Health Education Specialists (CHES), nurses, and advanced practice nurses. Please check back for more details soon!
